Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida. more
Time Frame | VERU | Sector | S&P500 |
---|---|---|---|
1-Week Return | -0.96% | -1.42% | 0.2% |
1-Month Return | 20.86% | 1.18% | 2.72% |
3-Month Return | -8.91% | -2.38% | 7.31% |
6-Month Return | -14.26% | 4.88% | 10.44% |
1-Year Return | 4.91% | 14.04% | 27.53% |
3-Year Return | -88.75% | 8.34% | 30.88% |
5-Year Return | -75.15% | 29.52% | 89.21% |
10-Year Return | -81.71% | 69.38% | 199.95% |
Sep '20 | Sep '21 | Sep '22 | Sep '23 | Sep '24 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 42.59M | 61.26M | 39.35M | 16.30M | 16.89M | [{"date":"2020-09-30","value":69.53,"profit":true},{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":64.24,"profit":true},{"date":"2023-09-30","value":26.6,"profit":true},{"date":"2024-09-30","value":27.57,"profit":true}] |
Cost of Revenue | 11.81M | 13.33M | 8.76M | 8.73M | 11.03M | [{"date":"2020-09-30","value":88.55,"profit":true},{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":65.73,"profit":true},{"date":"2023-09-30","value":65.49,"profit":true},{"date":"2024-09-30","value":82.75,"profit":true}] |
Gross Profit | 30.79M | 47.93M | 30.59M | 7.57M | 5.85M | [{"date":"2020-09-30","value":64.24,"profit":true},{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":63.83,"profit":true},{"date":"2023-09-30","value":15.79,"profit":true},{"date":"2024-09-30","value":12.21,"profit":true}] |
Gross Margin | 72.28% | 78.24% | 77.73% | 46.43% | 34.67% | [{"date":"2020-09-30","value":92.39,"profit":true},{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":99.36,"profit":true},{"date":"2023-09-30","value":59.34,"profit":true},{"date":"2024-09-30","value":44.31,"profit":true}] |
Operating Expenses | 45.53M | 53.36M | 113.81M | 103.11M | 43.99M | [{"date":"2020-09-30","value":40.01,"profit":true},{"date":"2021-09-30","value":46.89,"profit":true},{"date":"2022-09-30","value":100,"profit":true},{"date":"2023-09-30","value":90.59,"profit":true},{"date":"2024-09-30","value":38.65,"profit":true}] |
Operating Income | (14.75M) | (5.44M) | (83.22M) | (93.72M) | (38.14M) | [{"date":"2020-09-30","value":-1474669400,"profit":false},{"date":"2021-09-30","value":-543750100,"profit":false},{"date":"2022-09-30","value":-8322356000,"profit":false},{"date":"2023-09-30","value":-9371847700,"profit":false},{"date":"2024-09-30","value":-3813830500,"profit":false}] |
Total Non-Operating Income/Expense | (9.93M) | (13.59M) | (4.68M) | 2.93M | - | [{"date":"2020-09-30","value":-338.41,"profit":false},{"date":"2021-09-30","value":-463.41,"profit":false},{"date":"2022-09-30","value":-159.71,"profit":false},{"date":"2023-09-30","value":100,"profit":true},{"date":"2024-09-30","value":"-","profit":true}] |
Pre-Tax Income | (20.05M) | 4.27M | (83.54M) | (92.61M) | (37.08M) | [{"date":"2020-09-30","value":-470.13,"profit":false},{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":-1958.62,"profit":false},{"date":"2023-09-30","value":-2171.25,"profit":false},{"date":"2024-09-30","value":-869.27,"profit":false}] |
Income Taxes | (1.08M) | (3.13M) | 236.40K | 480.21K | 725.10K | [{"date":"2020-09-30","value":-148.73,"profit":false},{"date":"2021-09-30","value":-431.55,"profit":false},{"date":"2022-09-30","value":32.6,"profit":true},{"date":"2023-09-30","value":66.23,"profit":true},{"date":"2024-09-30","value":100,"profit":true}] |
Income After Taxes | (18.97M) | 7.39M | (83.78M) | (93.09M) | - | [{"date":"2020-09-30","value":-256.59,"profit":false},{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":-1132.97,"profit":false},{"date":"2023-09-30","value":-1258.92,"profit":false},{"date":"2024-09-30","value":"-","profit":true}] |
Income From Continuous Operations | (18.97M) | 7.39M | (83.78M) | (93.09M) | - | [{"date":"2020-09-30","value":-256.59,"profit":false},{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":-1132.97,"profit":false},{"date":"2023-09-30","value":-1258.92,"profit":false},{"date":"2024-09-30","value":"-","profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":"-","profit":true}] |
Net Income | (18.97M) | 7.39M | (83.78M) | (93.09M) | (37.80M) | [{"date":"2020-09-30","value":-256.59,"profit":false},{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":-1132.97,"profit":false},{"date":"2023-09-30","value":-1258.92,"profit":false},{"date":"2024-09-30","value":-511.22,"profit":false}] |
EPS (Diluted) | (0.08) | (0.14) | (1.05) | (1.19) | (0.28) | [{"date":"2020-09-30","value":-8,"profit":false},{"date":"2021-09-30","value":-14,"profit":false},{"date":"2022-09-30","value":-105,"profit":false},{"date":"2023-09-30","value":-119,"profit":false},{"date":"2024-09-30","value":-28.2,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
VERU | |
---|---|
Cash Ratio | 2.74 |
Current Ratio | 3.62 |
Quick Ratio | 3.16 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
VERU | |
---|---|
ROA (LTM) | -64.36% |
ROE (LTM) | -126.72% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
VERU | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.42 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.58 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
VERU | |
---|---|
Trailing PE | NM |
Forward PE | 117.65 |
P/S (TTM) | 7.41 |
P/B | 3.23 |
Price/FCF | NM |
EV/R | 5.53 |
EV/Ebitda | NM |
PEG | NM |
Veru Inc (VERU) share price today is $0.67
Yes, Indians can buy shares of Veru Inc (VERU) on Vested. To buy Veru Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VERU stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Veru Inc (VERU) via the Vested app. You can start investing in Veru Inc (VERU) with a minimum investment of $1.
You can invest in shares of Veru Inc (VERU) via Vested in three simple steps:
The 52-week high price of Veru Inc (VERU) is $1.92. The 52-week low price of Veru Inc (VERU) is $0.36.
The price-to-earnings (P/E) ratio of Veru Inc (VERU) is
The price-to-book (P/B) ratio of Veru Inc (VERU) is 3.23
The dividend yield of Veru Inc (VERU) is 0.00%
The market capitalization of Veru Inc (VERU) is $104.42M
The stock symbol (or ticker) of Veru Inc is VERU